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1  | INTRODUCTION
Approximately5%ofallhumancancersarecausedbyHPVinfection,
resultinginmorethan600000newcasesperyearworldwide.1 The 
cervix,penis,vulva,vagina,anus,andoropharynxareamongthetis-
suesforwhichtheInternationalAgencyforResearchonCancerhas
acknowledgedadirectcausalcorrelationbetweenHPVanddisease,
althoughthestrengthofthecorrelationdoesvary.2Therefore,HPVis
consideredthemostimportantoncogenicvirusaffectinghumansand
the primary cause of uterine cervical cancer.2
Among the high-risk genotypes for neoplastic transformation,
HPV16 and HPV18 show the most biologically aggressive behav-
ior and are the main contributors to HPV- related carcinogenesis.3 
However,otherhigh-riskgenotypesarealsoinvolvedincancertrans-
formation,withtheircontributionvaryingwithanatomicregion.Inthe
uterinecervix,thecontributionofnon-HPV16/HPV18genotypesto
HPV-relatedtumorgenesisisapproximately30%(Fig.1),whereasin
theanal,vulvovaginal,penile, andoropharyngealareas, their contri-
butionislessrelevant.4Twoavailablevaccines,oneofwhichisbiva-
lentagainstHPV16andHPV18(2vHPV)andtheotherquadrivalent
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Abstract
HPV-relateddiseasesaffectanogenitalandoropharyngealregions,heavilyaffecting
the psychosexual dimension of bothmale and female individuals.HPV vaccination
programsbasedonabivalentorquadrivalentvaccinehaveopenedbroadperspectives
forprimaryprevention.AnonavalentHPVvaccine(9vHPV),coveringninegenotypes
(HPV6,HPV11,HPV16,HPV18,HPV31,HPV33,HPV45,HPV52,andHPV58),might
providefurtherimprovementintermsofdirectprotection.Inthepresentreport,effi-
cacy and safety data from 9vHPV vaccine development programs are examined.
Efficacy data come from a pivotal trial,whichwas conducted amongwomen aged
16–26yearsrandomlyassignedtoreceiveeitherthe9vHPVorthequadrivalentHPV
(4vHPV)vaccine.The9vHPVvaccinewasshowntohavepotentialbenefitsascom-
paredwith 4vHPV, increasing the overall estimated rate of prevention to 90% for
cervical cancer and up to 80% for precancerous cervical lesions. For all other HPV- 
relatedpre-invasiveandinvasivelesions,9vHPVshowedpotentiallygreaterdisease
reduction, depending on the anatomic region examined. Thus, the 9vHPV vaccine
shows clinical potential for the prevention of HPV-related diseases in both sexes.
Future adoption of 9vHPV will depend on factors including market price, cost-
effectivenessdata,useofatwo-doseschedule,andsafetyandefficacymonitoringin
real- life programs.
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againstHPV6,HPV11,HPV16,andHPV18(4vHPV),haveshownhigh
efficacyagainst someclinical endpoints:more than90%prevention
ofhigh-gradeintraepitheliallesionsinthefemalegenitalarea(cervix,
vagina, andvulva), and for 4vHPVonly,more than90%prevention
of high- grade anal lesions in a post hoc case- assignment analysis and 
closeto100%preventionofgenitalwarts.5,6
Although indirect immune cross-reactivity has beendetected—
including protection against HPV31 with 4vHPV7 and against 
HPV31,HPV33,andHPV45with2vHPV8—thestrengthanddura-
tionoftheseevokedantibodyresponsesarelowerthanthoseofthe
targetedvaccinegenotypes,therebychallengingtheclinicalefficacy.
Indeed,recentreal-lifedatagatheredinEnglandonthe2vHPVvac-
cinefoundevidenceofareductionintheprevalenceofHPV31only,
and no relevant clinical impact on HPV33 and HPV45.9Therefore,a
directmultivalentapproach,arisingfromtheinclusionofsingleviral
genotypes,hasbecomeanadvancedobjectivetobroadenperspec-
tives in theprimarypreventionofHPV infection.This is the ratio-
nalebehindMerck’snonavalentvaccine(9vHPV),whichincludesfive
high-riskgenotypes(HPV31,HPV33,HPV45,HPV52,andHPV58),
in addition to those in the quadrivalent vaccine (HPV6, HPV11,
HPV16,andHPV18).
InDecember2014,9vHPVwasapprovedbytheUSFoodand
DrugAdministrationandrecommendedbytheAdvisoryCommittee
on Immunization Practices (ACIP).10 OnMarch 27, 2015, 9vHPV
also received a positive review from the European Medicines
AgencyCommitteeforMedicinalProductsforHumanUse(CHMP),
and on June 10, 2015, the European Commission approved it.
Furthermore,theCHMPalsogaveapositiveresponsetothetwo-
doseschedule.Theaimofthepresentreviewwastoexamine,with
a focus on Italian data, the potential clinical benefits and critical
issues of the nonavalent vaccine on the basis of currently available 
information.
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HPV- RELATED DISEASES
TheestimatedglobalprevalenceofcervicalHPVinfectionamongcy-
tologicallynormalwomenisapproximately10%(range8%–22%),with
significantregionaldifferencesandincreasedratesintheSub-Saharan
areaandEasternEuropeancountries.11InItaly,theprevalenceofpos-
itivehigh-riskHPVinthegeneralpopulationis9.2%.12
The direct correlation between HPV prevalence and women’s
age is well described, with rates being highest in younger women
and then gradually decreasing. Both global and Italian data indicate 
thattheprevalenceofHPVDNAincreaseswiththegradeofcervical
abnormality, frommild toseveredysplasia to invasivecarcinoma. In
high-gradecervicalintraepithelialneoplasia(CIN2+),HPV16isbyfar
themostprevalentgenotype(>60%),followedbyHPV18(10%–15%),
HPV31(15%),andHPV33(12%).Withregardtoinvasivecervicalcar-
cinoma,globaldatashowthatHPV16andHPV18accountforupto
70%ofcases,followedbyHPV45,HPV31,andHPV33(Fig.1).2 Italian 
data are consistent with these values.13–15
Inmen, theprevalence andnatural historyofHPV seems tobe
different,varyinggreatlybytissueororgan(shaft,glans,scrotum,and
urethra)andmethodofsamplecollection.Nevertheless,HPVpreva-
lenceishigherinmenthaninwomen,andisconstantovertimeamong
differentagegroups,therebyrepresentinga“reservoir”ofinfection.16 
Moreover,inselectedmalegroups(e.g.menwhohavesexwithmen,
especiallythosewithHIVinfection),HPVprevalencecanbeextremely
high(>70%)andisfrequentlyassociatedwithanalcarcinoma.17
TheprevalenceoforalHPVinfectionvarieswithstudyandmethod
ofcollection.Inhealthypopulationsinlow-incomecountries,theoral
HPVprevalencevariesbetween4.5%and6.9%,withthreefoldhigher
rates in men and in smokers than in women and in non-smokers,
respectively.18
EpidemiologicevaluationsaremoredifficultforHPV-relatedextra-
cervicalcancers,inmostofwhichonlyHPV16andHPV18arepres-
ent;however,asteadyincreaseinanalandoropharyngealneoplasms
has been reported in low- income countries.19 The interaction be-
tweenoropharyngealHPVinfectionandothercarcinogeneticagents
(e.g. smokeandalcohol),alongwitha lackofclearprecancerous le-
sions,makesitdifficulttoproperlyanalyzethecontributionofHPV.
Nevertheless,itshouldbenotedthat,atpresent,thereisnoapproved
screeningfornon-cervicalHPV-relatedcancers, thussupportingthe
importanceofvaccination.
The prevalence of HPV- related cancers in Italy has been recently 
updated:20newcasesofcervicalcancerhavebeenestimatedat2600
per year, cervical precancerous lesions at 29603–55625 per year,
vulvovaginal cancer cases at approximately 390 per year, and anal
cancercasesat366inmenand526inwomen.
Genitalwartsdeserveaspecificmention,becausetheyrepresent
themostwidespreadsexuallytransmittedinfectionworldwide,witha
peak incidence in young individuals aged 15–24 years. In more than 
90%ofcases,theyarerelatedtoHPV6andHPV11infection.InItaly,ep-
idemiologicdataongenitalwartshavebeengatheredfromthesentinel
F IGURE  1 ProportionofHPV-relatedcervicalcancers(squamous
and glandular lesions) attributed to different HPV genotypes. 
The seven more prevalent high- risk HPV genotypes (red bars) are 
includedinthe9vHPVvaccine;3 the other two genotypes included 
inthevaccinearelowrisk(HPV6andHPV11).Figurecreatedusing
datafromIARCmonographsontheevaluationofcarcinogenicrisks
tohumans,volume90LHumanPapillomaviruses.2Abbreviation:
9vHPV,nonavalentHPVvaccine.
     |  3Mariani ET aL.
surveillancesystemforsexuallytransmittedinfections,coordinatedby
theItalianNationalInstituteofHealth(IstitutoSuperiorediSanità),and
whichhavebeenfurtherconfirmedbyagynecologicnetworkstudy,21 
showing a high incidence of genital warts among individuals younger 
than25years,withanincreasingtrendinbothsexessince2004.
The relationship betweenHPV and human reproduction is cur-
rently thefocusofscientificresearch.Oneof thefirst retrospective
studiesofthepotentialassociationbetweenHPVandinfertilitywas
conductedbyaNorthAmericangroup,22 who correlated cervical HPV 
infection with reproductive outcomes of in vitro fertilization tech-
niquesamonginfertilepatients.Thestudyshowedasharpdecrease
in pregnancy amongHPV-positivewomen relative toHPV-negative
women(pregnancyrate23.5%vs57%,respectively).Similarly,apro-
spectivestudybyPerinoandcolleagues23,24amonginfertilecouples
undergoingassistedreproductivetechnologyfoundahigherincidence
of spontaneous abortionamongwomenwithpartnerswhose semi-
nalfluidtestedpositiveforHPVDNAthanamongwomenwithHPV-
negativepartners(66.7%vs15%,respectively).
AdebatedpointconcernstheassociationbetweenHPVinfection
andmale infertility.One studyhas reporteda relationshipbetween
viralinfectionandreducedmotilityofspermatozoa,supportingarole
for thevirusasacauseof idiopathicasthenozoospermia.25 Another 
studybyGolobetal.26 among 340 male members in couples experi-
encinginfertilityinSloveniadidnotfindthatHPVinfectioninfluenced
thequalityofsemen.ThisresultwasconsistentwiththatofSchillaci
etal.,27 who in turn demonstrated that the virus interacted with the 
equatorialregionofthespermatozoonhead.
Therefore,whilea scientificconsensuson ifand/orhowtoper-
form HPV screening among men and women eligible to undergo in 
vitro fertilization techniques is awaited, anextensionofvaccination
practicestothemalepopulationwouldbewelcome.
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VACCINATION
Since 2007, HPV vaccination programs have been organized na-
tionwideinalmostallhigh-resourcecountries.28 In low- and middle- 
income countries, many pilot studies are being conducted under
the guidance and support of the Global Alliance for Vaccines and
Immunization(GAVI).Conversely,incountriesrepresentingthepoor-
est regions of the world and subject to the highest risk of HPV infec-
tion,preventiveprogramsarealmostabsent. In fact, in thepoorest
regions,cervicalcancerhasthehighest incidenceandmortalityrate
among HPV-related cancers, whereas other forms (anal and oro-
pharyngeal)aremainlyincreasinginhigh-incomecountries.Therefore,
theobjectivesofHPVvaccinationshouldbecontinuallyupdatedand
redesignedconsistentwiththegeographicarea,reframingtheaimof
HPVvaccination inhigh-resourcecountries fromcontrolofcervical
cancer to control of all HPV- related diseases.
ItalianNationalInstituteofHealthdatapublishedinApril201529 
indicate that vaccination coverage reached approximately 71% in
over7yearssincethebeginningoftheorganizedprogram,although
therearesomelocaldifferences.Althoughthesedataarealongway
fromtheoriginaltargetof95%,theyarecompliantwithsubsequent
changesincludedinthe2012–2014NationalPreventionPlanandfol-
lowing agreements.30Forthcominglogisticeffortsmustfocusongrad-
uallyincreasingcoverageandcompliancetoreach95%ofthetarget
populationwiththecohortbornin2003.
Real-lifeHPVvaccinationprogramshave shown relevant clinical
benefits in reducing the prevalence of genital warts,31 HPV infec-
tions,32,33positivecervical smear results,34andhigh-gradeCIN.34–36 
However,somemethodologicaspectsofHPVvaccination,suchasthe
magnitudeanddurationofcross-protectionvaccineefficacy,arestill
debated.Eventhoughthepreregistrationstudiesofthetwocurrent
vaccines (2vHPV and 4vHPV)37,38 were not designed with the aim 
of investigatingcross-protectionefficacy,acertainamountofcross-
protectionwasproven.Givenmethodologicdifferencesbetweenthe
trials(e.g.inclusioncriteria,baselineprevalenceofHPV,demograph-
ics,andantibodydeterminationmethod),itisdifficulttocomparethe
data in termsof cross-protection.Additionally, such cross-reactivity
hasbeenshowntohavealowerintensityandshorterdurationascom-
paredwiththedirectevocationofvaccinegenotypes.7,39Asaresult,
the“directprotection”providedbyaddingnewgenotypestothevac-
cinewillprobablyovertakethedebateoncross-protection.
Although the number of HPV- related cancers in men is approxi-
matelyhalfthatinwomen,thereductioninvaccinepricehasmademale
vaccinationeconomically possible in some countries.Gender-neutral
vaccination(ongoinginAustralia,theUSA,Canada,Austria,Switzerland,
and eight Italian regions) prevents male HPV- related diseases5 and im-
provespublichealthinterventions,lowerstherateoftransmission,and
confirmstheprincipleofequalaccesstoprevention.39,40 As decided by 
theMinistryofHealth,universalHPVvaccinationofallindividualsaged
12 years will be undertaken in Italy from 2017.
4  | STUDY DESIGNS AND AVAILABLE 
RESULTS FOR 9vHPV
The9vHPVisanevolutionofthe4vHPV.Tofacilitatetheinclusionof
fivemorevirus-likeparticles(VLPs)fromhigh-riskgenotypes(HPV31,
HPV33,HPV45,HPV52,andHPV58),someadjustmentsweremadeto
theoriginalformulation(Table1):theamountofVLPsofthefourinitial
genotypeswasincreased,andthequantityofadjuvantwasdoubled.
Theclinicaldevelopmentprogramof9vHPVhasbeenorganized
intomanystudies(TableS1),someofwhichhavebeenpublished.41–44 
Themainobjectivesofsuchtrialswere:first,toinvestigatewhether
9vHPVhasalevelofimmunogenicitysimilartothatofthe4vHPVvac-
cineagainstinfectionscausedbyHPV6,HPV11,HPV16,andHPV18
(on the basis of the principle of non- inferiority of immune response); 
second,toproveclinicalefficacytowardinfectionsordiseasescaused
by the added genotypes (HPV31, HPV33, HPV45, HPV52, and
HPV58); third, to demonstrate non-inferior immunogenicity among
teenagersascomparedwithyoungwomen,apopulationinwhichclin-
ical protection has already been proven (immunobridging); and last,
toestablishwhetherthesafetyandtolerabilityprofileisacceptable.
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Thepivotalstudyon9vHPV(Study00141)wasarandomized,mul-
ticenter,double-blind,phase2–3studythatbeganin2009in19coun-
triesonfourcontinents.Thetrialenrolledmorethan14000women
aged16–26years,whowererandomlyassignedtoreceive9vHPVor
4vHPV vaccine. A direct clinical comparison of the new vaccine with 
placebo was not possible because of both ethical reasons and the need 
to enroll more than 45 000 women with more than 30 months of fol-
low-up.Thereportedefficacyresultsrefertotheper-protocolpopu-
lation,definedaswomenwhowereseronegative,PCR-negative,and
cytologicallynormalatbaseline,andwhocompletedthreedoseswithin
1yearwithnoprotocolviolations.Additionally,datafromthemodified
intention-to-treat(ITT)group,includingwomenwhoreceivedatleast
onevaccinedoseandatleastoneevaluationofefficacy,wereanalyzed.
In study 001,41 non-inferiority of the 9vHPV immune response
was demonstrated for the four genotypes in common with the 4vHPV 
vaccine.Seroconversioncloseto100%(fornewandpreviousvaccine
genotypes) was documented for all women enrolled (Table 2). In the 
per-protocolpopulation,clinicalprotectionwasdemonstratedagainst
thenewgenotypes(HPV31,HPV33,HPV45,HPV52,andHPV58)as
follows:96.7%forCINofgrade2orworse(CIN2+),vaginalintraep-
ithelial neoplasia of grade2 orworse (VaIN2+), andvulval intraepi-
thelialneoplasiaofgrade2orworse(VIN2+);and96%forpersistent
infection over 6months (Table3). Protection in the ITT groupwas
similar between 4vHPV and 9vHPV, resulting in an overall nonsig-
nificant reductionof cervical,vulvar, andvaginalhigh-gradedisease
forthe9vHPVvaccine.Therewasanincreaseintherateofadverse
events(swelling,erythema,andpruritus)atthesiteof9vHPVinjection
ascomparedwith4vHPV(90.7%vs84.9%).Similardataonsystemic
events were reported.
Amongtheotherpublishedprotocols,study00242 was designed 
to evaluate immunogenicity and immunobridging in boys and girls 
aged9–15yearsascomparedwithyoungwomenaged16–26years
for whom clinical efficacy data were available. Non-inferiority was
demonstrated for all new genotypes,with a seroconversion rate of
TABLE  2  Immunogenicity of the nonavalent HPV vaccine.a
Assay (cLIA)
4vHPV vaccine 9vHPV vaccine
Seroconversion, % GMT, mMU/mL Seroconversion, % GMT, mMU/mL
Anti-HPV6 99.8 875 99.8 893
Anti-HPV11 99.9 830 100 666
Anti-HPV16 100 3156 100 3131
Anti-HPV18 99.7 679 99.8 805
Abbreviations:cLIA,competitiveLuminex;GMT,geometricmeantiter;mMU,milli-Merckunits.
aDataobtainedfromJouraetal.41
TABLE  3 Clinicalendpointsof9vHPVversus4vHPV,byendpoint-relatedHPVgenotypes.a
Endpoint
4vHPV vaccine 9vHPV vaccine
Vaccine efficacy, %Cases/participants Cases/participants
HPV31,HPV33,HPV45,HPV52,HPV58
CIN2+,VIN2+,VaIN2+ 30/6017 1/6016 96.7
CIN2+ 27/5943 1/5948 96.3
HPV6,HPV11,HPV16,HPV18
CIN2+ 1/5832 1/5823 –
Anogenital warts 1/5893 5/5876 –
Abbreviations:9vHPV,nonavalentHPVvaccine;4vHPV,quadrivalentHPVvaccine;CIN2,cervicalintraepithelialneoplasiagrade2;VIN2+,vulvalintraepi-
thelialneoplasiagrade2orworse;ValN2+,vaginalintraepithelialneoplasiagrade2orworse.
aDataobtainedfromPetroskyetal.10
TABLE  1 CompositionofHPVvaccines.a
Vaccine Adjuvant
HPV genotype, μg
6 11 16 18 31 33 45 52 58
2vHPV 50 μgAS04 – – 20 20 – – – – –
4vHPV 225 μgAAHS 20 40 40 20 – – – – –
9vHPV 500 μgAAHS 30 40 60 40 20 20 20 20 20
Abbreviations:2vHPV,bivalentHPVvaccine;AS04,3-O-desacyl-4′-monophosphoryllipidA;4vHPV,quadrivalentHPVvaccine;AAHS,amorphousalu-
minumhydroxyphosphatesulfate;9vHPV,nonavalentHPVvaccine.
aDataobtainedfromhttp://www.ema.europa.eu/ema/(accessedNovember26,2016).
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99%across individualsofbothsexes.Thesedatasupportthebridg-
ing of efficacy results from adult women to boys and girls aged
9–15years.Amongmale individualsaged16–26years,theadminis-
trationof9vHPVwashighlyimmunogenic,showingaseroconversion
rateofmorethan99.5%.43
Last, safety results are available for all female individuals aged
12–26yearswhoreceiveda9vHPVdose.42 The new vaccine was gen-
erallywell tolerated, although therewas ahigher incidenceof local
reactions(e.g.pain,fever,anditch)ascomparedwith4vHPV.Because
9vHPVhasahighercontentofproteinsandadjuvant,thesedataare
consistent with what would be expected.
5  | POTENTIAL BENEFITS OF 9vHPV
TheextensionofprimaryprotectionisrelatedtothenumberofVLPs
includedinthevaccineformulation,inadditiontothepathogenicroleof
eachsinglegenotypeinspecificorgansandtissues.Takingintoaccount
thecontributionofHPVgenotypes, the femalegenitalarea—and the
uterinecervixparticularly—probablyhasthehighestpotentialtobenefit
from9vHPVprotection.Conversely,genotypicHPVvariabilityinother
anatomicareasislower,becauseHPV16andtoalesserextentHPV18
accountforalmostalloncologiccontributiontodiseaseintheseregions.
Giventhecontributionofthesinglegenotypes,45 the new nona-
valentvaccineformulationsubstantiallyexpands,by75%ormore,20 
thepotential topreventhigh-gradepre-neoplasticgenital lesionsas
comparedwith4vHPV.Specifically,theestimatedpreventionofHPV-
relateddiseaseisextendedby9vHPVfrom45.5%to82.3%forCIN2+
lesions, from82.2% to 94.4% forVIN2+, from64.1% to 77.7% for
VaIN2+, and from75.4% to81.5% for anal intraepithelial neoplasia
grade2orworse(AIN2+)inbothsexes(Figs2and3).
RegardingHPV-relatedcancers (Fig.4), theexpectedprevention
achieved by 9vHPV as comparedwith 4vHPV ranges from +2% to
+20%,dependingontheaffectedorgan.20,46Onthebasisofcontribu-
tionsofthevaccinegenotypes,ithasbeencalculatedthat9vHPVhas
thepowertopreventmorethan490000casesofHPV-relatedcancer
affectingthefemalegenitalarea,47 which would account for 87.4% of 
allcases.Similartopre-neoplasticlesions,thehighestpotentialbenefit
of9vHPVisobservedforcervicalcancer,inwhichtheestimatedaddi-
tionalpreventionoverthequadrivalentvaccinerangesfrom+14.7%46 
to+20%.20Anothermarkedobservation is the improvedprevention
ofanal cancer: theoverall expectedpreventionachievedby9vHPV
equals90%.45
The potential benefits of 9vHPV for other HPV-related neo-
plasms—theoretically including oropharyngeal cancers, although no
FIGURE 2 Proportion of HPV- related anogenital pre- cancer 
lesionsattributedtoviralgenotypesincludedin4vHPVand9vHPV.
Abbreviations:4vHPV,quadrivalentHPVvaccine;9vHPV,nonavalent
HPVvaccine;CIN2+,cervicalintraepithelialneoplasiagrade2orhigher;
VIN2+,vulvalintraepithelialneoplasiagrade2orhigher;ValN2+,vaginal
intraepithelialneoplasiagrade2orhigher;AIN2+,analintraepithelial
neoplasia grade 2 or higher. Figure created using data from Hartwig 
et al.20
FIGURE 3 Proportion of HPV- related cervical pre- cancer lesions 
attributedtoviralgenotypesincludedin4vHPVand9vHPVasreported
in literature.20,45,46Abbreviations:4vHPV,quadrivalentHPVvaccine;
9vHPV,nonavalentHPVvaccine;CIN,cervicalintraepithelialneoplasia.
F IGURE  4 Proportion of all HPV- related cancers attributed to 
viralgenotypesincludedin4vHPVand9vHPVasreportedinthe
literature.20,46,47Abbreviations:4vHPV,quadrivalentHPVvaccine;
9vHPV,nonavalentHPVvaccine.
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vaccinehasbeenapprovedasyet—arelower.Infact,vaccineefficacy
remainsclinicallyunprovenintheoropharyngealtract,althoughare-
ducedprevalenceofvaccinegenotypesafteradministrationof2vHPV
hasbeenreportedinaCostaRicantrial.48However,itseemsreason-
able that thebiomolecularmechanismsunderlyingHPVvaccination
willresultinhighclinicalprotectionalsointheheadandneckarea,as
they do in the anogenital tract.
6  | CRITICAL ISSUES
Giventheclinicalbackgroundoutlinedabove,9vHPVraisessomepo-
tential issues.Thesimilarclinicalefficacyobservedbetween9vHPV
and4vHPVintheITTgrouprequiresacomment.Womenwithpreva-
lentcervicaldiseaseor infectionarenotexcluded from ITTgroups,
andmighttherebycontributetothedecreasedefficacyofthevaccine.
Thiswasthecaseinstudy001,inwhichmanyoftheyoungpartici-
pants(aged16–26years)werefoundtobealreadyinfectedwiththe
additionalfiveHPVtypesinthenewvaccineatbaseline.Althoughthe
efficacyofaprophylacticvaccinemustbeevaluatedamongwomen
whohavenotbeenexposedtoHPV(perprotocol),inthecontextof
organizedreal-lifevaccinationanon-negligiblenumberofindividuals
could already be infected with HPV.
Additionally,amethodologicissuearisesfromthelackofaplacebo
groupinstudy001.However,thisunusualhybridapproach, using a dif-
ferentmethodofevaluationfortheoriginalgenotypes(immunogenic
endpoint) and theaddedones (clinical endpoint),wasnecessary for
ethical reasons.
Othercriticalissuesof9vHPVvaccineincludethecostanddose
schedule,bothimportantconsiderationsinlightoffundingprograms
establishedbysingleregionsofsomecountrieswhere,asinItaly,or-
ganizedvaccinationprogramsareregionalized.Arecentstudyinthe
USA49suggeststhattheswitchfrom4vHPVto9vHPVwithinauni-
versalgender-neutralprogramwouldremaincost-effectiveaslongas
thepriceincreaseforonedosedoesnotexceedUS$13.
Concerning the dose number, in February 2016, the European
CHMPgave a preliminary positive opinion on the two-dose sched-
ule (as opposed to the three- dose schedule) for girls younger than 
15years.Thisreduceddosageisanunavoidableprerequisiteofana-
tionalvaccinationprogram,owing to thehealthcost savingsand to
highercompliancebythetargetpopulation.
The management of the switch from one generation of vac-
cinestoanotherraisessomemattersofdebateduringtheongoing
organized national programs. Individuals vaccinated with 2vHPV
or 4vHPVmight request either to have the 9vHPVvaccinationor
to complete an incomplete schedule with it. As stated recently by 
theACIP, itwill be important to have national or regional recom-
mendationsonwhattodointhecaseofrevaccinationoranincom-
plete vaccination schedule to be able to transition to the 9vHPV
vaccine.10 From thisperspective, it is important to clarify that the
administrationof9vHPVtowomenalreadyvaccinatedwith4vHPV,
asapprovedbytheACIP,hasalreadydemonstratedhighsafetyand
immunogenicity.44
7  | FUTURE PERSPECTIVES AND CLOSING  
REMARKS
ThediseasecausedbyHPVinfectionrepresentsamajorsocialhealth
problem for male and female individuals in both low- and high- income 
countries.Theclinicaloutcomesofbenign,preneoplastic, and inva-
siveHPV-relateddiseaseplayanimportantpartinhealthexpenditure,
requiringhugeeconomicresourcesandheavilyaffectingthepsycho-
sexualdimensionofthepopulation.
Beyond the implementation and efficacyof organized screening
programs, the possibility of primary prevention throughvaccination
haswidenedperspectives.Throughthe2vHPVand4vHPVvaccines,
importantclinicalbenefitshavebeenachievedinthevaccinatedpop-
ulation.The9vHPVvaccinemight represent a true turningpoint in
termsofdirectpreventionofahighernumberofHPV-relatedcancers.
Ascomparedwith4vHPV,thenonavalentvaccinehasthepotentialto
further reduce the prevalence of both pre- invasive and invasive ano-
genital lesions from6%to20%,dependingon theanatomic region.
Majorbenefitsareexpectedagainst cervical cancerand, toa lesser
level,againstvulvovaginalandanalcancers.
Theadoptionandimplementationof9vHPVwilldependonmar-
ketprice,cost-effectivenessdata,andtheuseofatwo-dosesched-
uleamongteenagers.Moreover,asinthecaseof2vHPVand4vHPV,
safetyandefficacymonitoringinreal-lifepopulationprogramswillbe
neededforthisvaccine.Onthebasisofthedatareviewedhereinand
theanalysisofpre-registrationstudies,9vHPVhasimportantclinical
potential and might represent an innovation for the prevention of
HPV- related diseases for both men and women.
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